This page is kept for reference and is not offered to search engines.
Indication
Extavia is indicated for the treatment of: patients with a single demyelinating event with an active inflammatory process, if it is severe enough to warrant treatment with intravenous corticosteroids, if alternative diagnoses have been excluded, and if they are determined to be at high risk of developing clinically definite multiple sclerosis; patients with relapsing-remitting multiple sclerosis and two or more relapses within the last two years; patients with secondary progressive multiple sclerosis with active disease, evidenced by relapses.
In other countries
The same active substances on other registers, the same brand first.
- ExtaviaCanada · 0.3 MG / VIAL · Powder For Solution · Novartis Pharmaceuticals Canada INCSame brand
- Extavia 250 Microgramos/ML Polvo y Disolvente Para Solucion InyectableSpain · 250 µg · polvo y solución para solución inyectable · Novartis Europharm LimitedSame brand
- ExtaviaUnited States · 0.3MG · For Injection · Novartis Pharmaceuticals CorporationSame brand